Table 3.

Trials Evaluating tamoxifen benefit on node negative, breast cancer all ages.

	Total # of patients	Age ≥ 70 years # of patients	Randomization	Disease-free survival	Overall survival
NSABP B14 N. Eng. J. Med. 1989	2817	0	ET vs No ET	P < 0.00001	No diff: in >50 yrs. P = 0.13
BASO II Eur. J. Cancer 2013	1135	0	ET vs RT vs RT + ET vs Observation	NR	No diff
GBSG-V Eur. J. Cancer 2010	347	NR	ET vs RT vs RT + ET vs Observation	No diff	No diff
NSABP B21 JCO 2002	1009	159	ET vs RT vs RT + ET	No diff P = 0.28	No diff P = 0.93

NR not reported.